Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, Elanco Animal Health Incorporated reported revenue of $4.71B, up 6.2% year over year. Operating margin was n/a and net margin -4.9%, on a free-cash-flow margin of 6.0% with capital expenditure at 5.9% of revenue. Every figure is computed directly from ELAN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4.71B | n/a | -4.9% |
| FY2024 | $4.44B | 11.0% | 7.6% |
| FY2023 | $4.42B | -27.1% | -27.9% |
| FY2022 | $4.41B | -1.6% | -1.8% |
| FY2021 | $4.76B | -12.0% | -10.1% |
How does ELAN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.